Activest Wealth Management’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.34K Hold
303
﹤0.01% 597
2026
Q1
$6.54K Hold
303
﹤0.01% 776
2025
Q4
$7.22K Hold
303
﹤0.01% 721
2025
Q3
$4.12K Hold
303
﹤0.01% 676
2025
Q2
$2.47K Hold
303
﹤0.01% 658
2025
Q1
$2.38K Hold
303
﹤0.01% 626
2024
Q4
$4.51K Hold
303
﹤0.01% 381
2024
Q3
$4.63K Hold
303
﹤0.01% 367
2024
Q2
$4.62K Hold
303
﹤0.01% 348
2024
Q1
$5.72K Hold
303
﹤0.01% 250
2023
Q4
$5.79K Hold
303
﹤0.01% 221
2023
Q3
$5.44K Hold
303
﹤0.01% 219
2023
Q2
$5.88K Hold
303
﹤0.01% 208
2023
Q1
$5.29K Hold
303
﹤0.01% 208
2022
Q4
$6.27K Hold
303
﹤0.01% 338
2022
Q3
$8K Hold
303
﹤0.01% 318
2022
Q2
$8K Hold
303
0.01% 219
2022
Q1
$10K Hold
303
0.01% 206
2021
Q4
$12K Hold
303
0.01% 196
2021
Q3
$11K Hold
303
0.01% 221
2021
Q2
$8K Hold
303
0.01% 226
2021
Q1
$9K Buy
+303
New +$10.5K 0.01% 202

Other funds holding RCUS

Activest Wealth Management's RCUS Position: Q2 2026 in Review

Activest Wealth Management held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 303 shares worth $9.34K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

Activest Wealth Management first reported a position in RCUS in Q1 2021 and has held it in 22 quarters since. The position peaked at $12K in Q4 2021. 32 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Activest Wealth Management held 303 shares of Arcus Biosciences worth $9.34K as of Q2 2026.
  • Activest Wealth Management left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Activest Wealth Management's portfolio in Q2 2026, its #597 holding.
  • Activest Wealth Management first reported a position in Arcus Biosciences in Q1 2021 and has held it in 22 quarters since.
  • Activest Wealth Management's Arcus Biosciences position peaked at $12K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Activest Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.